I have heard that Cypress has an appointment with the FDA in October to discuss the Phase lll Indaflex. Hopefully, that would mean starting the trial relatively quickly thereafter. I have also heard that the TSX Venture listing should occur in late July. At that point, there should be more buying and the stock price could firm up.
Finally, a nephew of mine who is a PharmD and MS in medical economics and has a job with a big drug company, follows ALRX and is very impressed with the new drugs, perhaps more so than Indaflex. He likes the company strategy of taking existing drugs and improving their effectiveness through the unique delivery system.
Let's keep our fingers crossed.
